Novo Nordisk Balances Growth with Environmental Progress Amid Rising Demand

Novo Nordisk is navigating a complex challenge that is becoming increasingly common across the pharmaceutical and life sciences sector. Rapid growth driven by rising global demand for diabetes and obesity treatments is requiring major expansions in manufacturing capacity, logistics, and supply chains. At the same time, the company is under growing pressure to demonstrate that this growth can be achieved without undermining climate and environmental commitments.

Recent disclosures show that Novo Nordisk has continued to make progress on environmental performance, while openly acknowledging the structural tensions between scale, speed, and sustainability. The company’s experience provides a useful case study for how high-growth healthcare businesses are approaching net-zero ambitions in practice.

Managing Emissions Growth in a Scaling Business

Novo Nordisk has adopted science-based climate targets aligned with limiting global warming to 1.5 degrees Celsius. These targets cover Scope 1 and 2 emissions from direct operations and purchased energy, as well as Scope 3 emissions across the value chain.

As production volumes increase, the company reports that emissions intensity has improved, even though absolute emissions can rise in the short term. New manufacturing sites, expanded facilities, and increased output naturally lead to higher energy demand, particularly during construction and early operational phases. Novo Nordisk frames this as a transitional challenge rather than a departure from its long-term climate trajectory.

This approach reflects a broader shift within the sector, where companies are increasingly transparent about the difference between relative efficiency gains and absolute emissions reductions.

Renewable Electricity and Energy Efficiency as Core Levers

Energy sourcing remains one of the most effective tools available to reduce operational emissions. Novo Nordisk has significantly increased its use of renewable electricity across global sites, primarily through power purchase agreements and renewable energy certificates.

Several production facilities already operate on 100% renewable electricity, and new sites are being designed with low-carbon energy integration from the outset. In parallel, the company continues to invest in energy efficiency through improved process design, automation, heat recovery systems, and building optimisation.

These measures not only reduce emissions but also help manage long-term energy costs and exposure to energy price volatility, an increasingly relevant consideration for energy-intensive manufacturing sectors.

Water Stewardship Under Increasing Pressure

Water use is a material issue for pharmaceutical manufacturing, particularly as production scales up. Novo Nordisk reports ongoing efforts to reduce water consumption per unit of output and to improve wastewater treatment performance.

In regions exposed to higher water stress, the company is implementing site-specific water stewardship plans. These include water reuse systems, improved monitoring, and collaboration with local stakeholders to strengthen water resilience. While progress has been made, the company acknowledges that expanding production inevitably increases total water demand, reinforcing the need for careful site planning and long-term water risk assessment.

Packaging, Waste, and Circularity Constraints

Waste management and packaging are additional areas under scrutiny. Novo Nordisk has committed to reducing waste sent to landfill and increasing recycling rates across its operations. Production waste streams are being reviewed to identify opportunities for material recovery and improved treatment.

Product packaging presents a more complex challenge. Strict regulatory requirements for medical safety limit the pace at which packaging materials can be changed. Nevertheless, the company is working to reduce material use, increase recyclability, and engage with regulators and industry partners on longer-term solutions that align safety and sustainability objectives.

Scope 3 Emissions Remain the Largest Challenge

The majority of Novo Nordisk’s carbon footprint sits within Scope 3 emissions, including raw materials, contract manufacturing, transport and product use. Addressing these emissions requires influence rather than direct control, making progress slower and less predictable.

The company has expanded supplier engagement programmes, requesting emissions data and encouraging key suppliers to set science-based targets. While progress has been achieved with strategic partners, data quality and coverage across the wider supplier base remain uneven. This reflects broader structural challenges across pharmaceutical supply chains, where traceability and standardised reporting are still evolving.

Governance and Decision-Making Integration

Sustainability considerations are increasingly embedded within Novo Nordisk’s governance framework. Environmental targets are linked to executive incentives, and climate-related risks are assessed alongside financial and operational risks.

This integration signals a shift away from sustainability as a standalone reporting exercise, toward a model where environmental performance influences capital investment, site selection, and supplier relationships. For investors, this approach provides greater visibility into how climate risks and opportunities are managed at a strategic level.

Implications for the Pharmaceutical Sector

Novo Nordisk’s experience highlights the constraints facing high-growth healthcare companies operating within planetary boundaries. Efficiency improvements and renewable energy can deliver meaningful progress, but absolute emissions reductions become more difficult during periods of rapid expansion.

The case reinforces the importance of system-level solutions, including decarbonized power grids, low-carbon materials, and regulatory frameworks that enable sustainable product design without compromising patient safety. It also underlines the value of planning sustainability into expansion strategies from the earliest stages, rather than relying on retrofits.

Balancing Health Outcomes and Environmental Limits

As global demand for essential medicines continues to rise, pharmaceutical companies will increasingly be judged on their ability to deliver health outcomes while respecting environmental limits. Novo Nordisk’s current trajectory suggests that progress is possible, but rarely linear.

Incremental gains, transparent reporting, and long-term investment appear to be the defining features of this transition. How effectively the company maintains this balance over the coming years will offer important signals for the wider life sciences sector as it navigates the path toward net-zero.

Source: sustainabilitymag.com